Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 7,51 € (+47,54%). Mediana wynosi 7,79 € (+53,05%).
| Kupuj |
5 |
| Trzymaj |
0 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
ALX Oncology presents preclinical data on EGFR‑ADC candidate ALX2004 and starts phase‑1
ALX Oncology presented preclinical data and the study design for the EGFR‑targeted ADC candidate ALX2004 at AACR‑NCI‑EORTC 2025. The phase‑1 first‑in‑human study began in August; initial safety data are expected in H1 2026. ALX2004 uses an antibody derived from Matuzumab and an improved linker‑payload platform to reduce skin toxicity and enhance bystander effects. The company reports a strong liquidity position; investors will watch study progress, cash burn and the quarterly report on 6 November. » Więcej na de.investing.com
ALX Oncology appoints Dr. Barbara Klencke as interim CMO
ALX Oncology has appointed Dr. Barbara Klencke as interim chief medical officer; she will resign her supervisory board mandate to take the role. The previous CMO, Dr. Alan Sandler, is returning to his former supervisory board seat. The company, with a market valuation of about USD 63 million and a high cash burn rate, reported Q2/2025 EPS of -0.49 USD, missing expectations. In parallel, ALX launched a phase‑1 study of the antibody‑drug conjugate ALX2004, while the clinical development of Evorpacept continues. » Więcej na de.investing.com
ALX Oncology Holdings Inc. starts phase-1 study for EGFR cancer drug and treats first patient
ALX Oncology Holdings Inc. has treated the first patient in the phase-1 study of its EGFR-targeting antibody-drug conjugate and expects initial safety data in the first half of 2026. The company shows a strong liquidity position (current ratio 4.52), but missed analysts' expectations in Q2 2025 with EPS of -$0.49. The stock recently showed strong price momentum with a roughly 58% weekly gain. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 141,32 mln | 39,03% |
| Zysk brutto | 0 | 100,00% |
| Zysk netto | -8,58 mln | 40,56% |
| EBITDA | -2,43 mln | 78,69% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 444,03 mln € |
Liczba akcji | 99,98 mln |
Maksimum/minimum z 52 tygodni | 6,10 € - 2,01 € |
| Dywidendy | Nie |
Beta | 0,42 |
C/Z (PE Ratio) | -20,57 |
PEG (PEG Ratio) | 0,31 |
C/WK (PB Ratio) | -25,52 |
C/S (PS Ratio) | 1,05 |
Profil spółki
The Oncology Institute, Inc. ist ein Onkologieunternehmen, das in den Vereinigten Staaten medizinische Onkologiedienste anbietet. Zu seinen Leistungen gehören ärztliche Dienste, hauseigene Infusionen und Dispenser, klinische Studien, Bestrahlung, ambulante Stammzellentransplantationen und Transfusionsprogramme sowie Patientenbetreuung. Das Unternehmen bietet auch Dienstleistungen für klinische Studien an und verwaltet diese, z. B. die Verwaltung klinischer Studien, Palliativprogramme und Stammzellentransplantationen. Das Unternehmen betreut erwachsene und ältere Krebspatienten. Das Unternehmen betreibt 67 Klinikstandorte. The Oncology Institute, Inc. wurde im Jahr 2007 gegründet und hat seinen Sitz in Cerritos, Kalifornien.
| Nazwa | ONCOLOGY INST. A DL-,0001 Aktie |
| CEO | Daniel Virnich |
| Siedziba | Cerritos,
ca Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Ochrona zdrowia: świadczeniodawcy i usługi |
| Debiut giełdowy | 04.06.2020 |
| Pracownicy | 641 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | TOI |
